Bevacizumab Adoption Tied to Use by Peers
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
Ovarian Cancer
New Research Says There’s No Significant Link Between Talc and Ovarian Cancer, but Some Scientists Push Back Against the Study’s Data and Design
Some experts say the talc study’s data limitations weaken its impact in the field.
Fertility-Sparing Surgery Achieves Good Oncologic, Obstetric Outcomes in Younger Women With Early-Stage Nonepithelial Ovarian Cancer
In this first reported prospective study, researchers compared outcomes of fertility-sparing surgery with radical surgery in women with stage I nonepithelial ovarian cancer.
PALB2 Linked to Increased Risk for Breast, Ovarian, and Pancreatic Cancer
Germline PALB2 pathogenic variants were associated with an increased risk of female or male breast cancer, as well as ovarian and pancreatic cancer.
Addition of Maintenance Olaparib Slows Advanced Ovarian Cancer
Benefit substantial for homologous-recombination deficiency positive tumors with, without BRCA mutations
Testing for Genetic Variants Informed the Use of Cancer Risk Assessments
Genetic testing provided important information beyond personal and family history.
Secondary Surgical Cytoreduction Not Superior in Ovarian Cancer
Addition of surgery prior to chemotherapy does not prolong overall survival in recurrent ovarian cancer.
Multitumor “Exceptional Responder” Program in Australia Seeks to Gain Clinical Context
The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response.
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer
In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
Zejula Approved for Late-line Treatment of Recurrent Ovarian Cancer
Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Next post in Gynecologic Cancer
